HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Raises Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce reiterated a Buy rating on Travere Therapeutics (NASDAQ:TVTX) and raised the price target from $22 to $35.
June 01, 2023 | 3:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Travere Therapeutics (NASDAQ:TVTX) receives a reiterated Buy rating from HC Wainwright & Co. analyst Ed Arce, with an increased price target of $35.
The news of a reiterated Buy rating and an increased price target from $22 to $35 by HC Wainwright & Co. analyst Ed Arce is positive for Travere Therapeutics. This shows confidence in the company's potential and is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100